7 July 2026

Osteopore achieves market access to Saudi Arabia for its craniofacial products

Highlights

- **Osteopore is delighted to announce that it has achieved market access to Saudi Arabia for its craniofacial products, distributed in partnership with Zimmer Biomet (NYSE and SIX: ZBH).**
- **As previously announced on 16 July 2024[1], Osteopore entered into an agreement with Zimmer Biomet to distribute Osteopore's craniofacial products in Europe, the Middle East, and Africa (EMEA) and Asia Pacific (APAC) including Australia and New Zealand.**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that it has achieved market access to Saudi Arabia for its craniofacial products, distributed in partnership with Zimmer Biomet.

As previously announced on 16 July 2024[1], Osteopore entered into an agreement with Zimmer Biomet to distribute Osteopore's craniofacial products in EMEA and APAC. As part of a progress update, Osteopore announced on 29 July 2025[2] that sales had commenced in Europe, Australia and Hong Kong, with the number of implants sold from these countries growing

[1] ASX announcement, "Osteopore strikes Exclusive Distribution with Zimmer Biomet", 16 July 2024.

[2] ASX announcement, "Business progress update, Zimmer Biomet sales units grows 3x", 29 July 2025.

three-fold from 2024 H2 to 2025 H1, in comparison to the 12 months prior (2023 H2 to 2024 H1).

This latest market access update reflects the continued collaboration between Osteopore and Zimmer Biomet, and their shared commitment to accelerate accessibility of Osteopore's regenerative implants for healthcare practitioners and patients.

Saudi Arabia is a country within the EMEA distribution partnership. It is the largest economy in the Middle East and the *de facto* leader of the Gulf Cooperation Council, with its population and advanced healthcare infrastructure under Vision 2030 widely regarded as the clinical and commercial benchmark for the broader GCC.

Market access in Saudi Arabia is therefore widely viewed by global medical technology companies as a key reference point that supports market entry across the wider Gulf region.

Zimmer Biomet established a commercial presence in Saudi Arabia in 2018, building a team across clinical, sales, operations, and warehousing functions. The Company has since further deepened its regional commitment, opening a dedicated regional headquarters in Saudi Arabia focused on physician education and training[3].

The strategic initiatives undertaken by Zimmer Biomet provide an opportunity for Osteopore's products to leverage an established and well-resourced pathway to market in both Saudi Arabia and, given Saudi Arabia's role as a regional reference market, the broader GCC.

The global craniomaxillofacial implants market was valued at approximately USD 3 billion in 2026 and is projected to grow at a compound annual growth rate of approximately 9.7% to 2030[4]. The Middle East and Africa region represents approximately 7% of this global market[5],

[3] https://pharmaboardroom.com/interviews/amr-kenawi-general-manager-zimmer-biomet-saudi-arabia/

[4] https://www.fortunebusinessinsights.com/industry-reports/craniomaxillofacial-implants-market-101031

[5] https://www.reanin.com/reports/craniomaxillofacial-implants-market

with Saudi Arabia recognised as the region's largest and most established craniomaxillofacial implant market.

On this basis, the Company estimates the addressable Saudi Arabia market for craniomaxillofacial implants, inclusive of patient-specific implants, to be in the order of USD 60–80 million, growing in line with broader global market trends.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.